IL2 and COVID-19: First, we compared the prevalence, magnitude, and phenotypical profile of SARS-CoV-2–responding CD4+ T cells (e.g., cells producing IFN-γ, TNF-α, or IL-2; Figure 2A) between hospitalized non–COVID-19 controls and confirmed COVID-19 patients.